株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオ医薬品受託製造市場 (第2版):2017-2027年

Biopharmaceutical Contract Manufacturing Market (2nd Edition), 2017 - 2027

発行 ROOTS ANALYSIS 商品コード 329397
出版日 ページ情報 英文 556 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.65円で換算しております。
Back to Top
バイオ医薬品受託製造市場 (第2版):2017-2027年 Biopharmaceutical Contract Manufacturing Market (2nd Edition), 2017 - 2027
出版日: 2017年05月18日 ページ情報: 英文 556 Pages
概要

当レポートでは、バイオ医薬品受託製造市場の現状と将来的見通しについて調査し、市場の概要、競合情勢、市場動向と今後の見通し、主要地域/国における市場の分析と予測、ニッチ市場の概要、近年の発展動向、ケーススタディおよび市場のSWOT分析などを提供しています。

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 概要と背景
  • バイオ医薬品:概要
  • バイオ医薬品:製造工程
  • 受託製造:概要
  • バイオ医薬品産業におけるアウトソーシングのニーズ
  • バイオ医薬品受託製造:一般的なアウトソース工程
  • バイオ医薬品受託製造:主なCMO提携企業
  • バイオ医薬品受託製造:関連リスク・課題

第4章 競合情勢

  • 本章の概要
    • バイオ医薬品CMOの地域プレゼンス
    • 分析:生物製剤の種類
    • 分析:経営規模
    • 分析:発現システム
    • 分析:バイオリアクターの種類・オペレーション形態
    • 分析:製造能力
    • 分析:パッケージングフォーム

第5章 北米におけるバイオ医薬品受託製造

  • 本章の概要
  • 北米におけるバイオ医薬品アウトソーシング:規制状況
    • 現在の政治的状況の影響
  • 北米における主なバイオ医薬品CMO
    • AMRI
    • Baxter BioPharma Solutions
    • Catalent
    • Cytovance Biologics
    • Patheon
  • 北米におけるバイオ医薬品受託製造:2次市場の予測
    • 企業活動
    • 発現システム

第6章 欧州におけるバイオ医薬品受託製造

  • 本章の概要
  • 欧州におけるバイオ医薬品アウトソーシング:規制状況
  • 欧州における主なバイオ医薬品CMO
    • 3P Biopharmaceuticals
    • Boehringer Ingelheim BioXcellence
    • Celonic
    • FUJIFILM Diosynth Biotechnologies
    • LFB Biopharma
    • Lonza
    • Menarini Biotech
    • Novasep
    • Rentschler Biotechnologie
  • 欧州におけるバイオ医薬品受託製造:2次市場の予測
    • 企業活動
    • 発現システム

第7章 アジア・その他地域 (ROW) におけるバイオ医薬品受託製造

  • 本章の概要
  • 中国におけるバイオ医薬品アウトソーシング
  • 中国における主なバイオ医薬品CMO
    • Autotek Bio
    • WuXi AppTec
  • 中国におけるバイオ医薬品受託製造:2次市場の予測
  • インドにおけるバイオ医薬品アウトソーシング
  • インドにおける主なバイオ医薬品CMO
    • Intas Pharmaceuticals
    • Kemwell Biopharma
    • Piramal Pharma Solutions
    • Shashun Pharma
    • Syngene
  • インドにおけるバイオ医薬品受託製造:2次市場の予測
  • 日本におけるバイオ医薬品アウトソーシング
  • 日本における主なバイオ医薬品CMO
    • 旭硝子
  • 日本におけるバイオ医薬品受託製造:2次市場の予測
  • 韓国におけるバイオ医薬品アウトソーシング
  • 韓国における主なバイオ医薬品CMO
    • DMBio
    • Samsung BioLogics
  • 韓国におけるバイオ医薬品受託製造:2次市場の予測
  • オーストラリアにおけるバイオ医薬品アウトソーシング
  • オーストラリアにおける主なバイオ医薬品CMO
    • Cell Therapies
    • LuinaBio
  • オーストラリアにおけるバイオ医薬品受託製造:2次市場の予測

第8章 バイオ医薬品受託製造におけるニッチ市場

  • 本章の概要
  • 抗体薬物複合体 (ADC)
  • 二重特異性抗体
  • 細胞療法
  • 遺伝子療法

第9章 ケーススタディ:バイオシミラーのアウトソーシング

  • 本章の概要
  • バイオシミラー:イントロダクション
  • バイオシミラー:開発・製造作業のアウトソーシングのニーズ
  • 世界の受託製造市場におけるバイオシミラーの影響
    • パイプライン分析
    • 地域動向
    • 受託サービスプロバイダー
  • バイオシミラー:アウトソーシング関連の課題

第10章 近年の発展動向

  • 本章の概要
  • バイオ医薬品受託製造市場:提携
  • バイオ医薬品受託製造市場:近年の発展動向
  • バイオ医薬品受託製造市場:財政的支援の実例
  • バイオ医薬品受託製造市場:技術進歩

第11章 製造能力分析

  • 本章の概要
  • 予測の前提条件・予測手法
  • バイオ医薬品CMO:世界的な製造能力
  • 結論

第12章 調査分析

  • 本章の概要
  • 生物製剤製造専門企業
  • 製造規模
  • 生産施設のロケーション
  • 発現システムの種類
  • バイオリアクターの種類
  • バイオリアクターのオペレーション形態

第13章 機会分析

  • 本章の概要
  • 予測手法
  • 全体的なバイオ医薬品CMO市場
  • バイオ医薬品CMO市場:発現システム別の分析
  • バイオ医薬品CMO市場:地域的な分布

第14章 SWOT分析

  • 本章の概要
  • 強み
  • 弱み
  • 機械
  • 脅威
  • 結論

第15章 バイオ医薬品CMO市場の将来

第16章 インタビュー原稿

第17章 付録I:表形式データ

第18章 付録II:企業・組織のリスト

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: RA10082

Over the years, the biopharmaceutical market has grown into a prominent and promising segment of the overall pharmaceutical industry. Characterized by a number of blockbuster therapies (HUMIRA®, RITUXAN®, Lantus®, Avastin®, Herceptin® and REMICADE®) and a robust pipeline of product / therapy candidates, the market is poised for significant growth in the coming years. It is worth mentioning that much of the anticipated success of the biopharmaceutical market is dependent on new biologics, which are currently under development, and biosimilars, which are generic versions of these biologics. The field continues to witness significant growth in terms of innovation; this activity is clearly indicative of the growing demand for biologics to cater to existing unmet needs in the industry.

It is necessary to highlight the fact that the development and manufacturing processes for biologics are complex, and usually require advanced capabilities and specialized expertise. In addition, the costs associated with acquiring capabilities in this field are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. These complications have led many stakeholders in the biopharmaceutical industry to outsource significant parts of their business operations to contract service providers.

As a result of the above mentioned industry dynamics, the contract manufacturing industry landscape is steadily evolving. CMOs aiming to consolidate their presence in the market are rapidly expanding their service portfolios to provide end-to-end services to their clients and sponsors.

Synopsis:

The ‘Biopharmaceutical Contract Manufacturing Market (2nd edition), 2017 - 2027’ report provides an extensive study of the contract manufacturing market for biopharmaceuticals. As the biotechnology industry continues to strive to maximize profits, outsourcing has emerged as a promising trend. The study features in-depth analysis, highlighting capabilities of a diverse set of biopharmaceutical CMOs. In addition to other elements, it provides information on the following:

  • The competitive market landscape and industry analysis based on a number of parameters, such as geographical location, scale of operation, type of biologics manufactured, expression systems used, type of bioreactors used, mode of operation of bioreactors and bioprocessing capacity.
  • Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance, information on its manufacturing service and facilities, partnerships and recent developments.
  • A detailed discussion on the key enablers, including certain niche sub-segments, such as ADCs, bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
  • A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical contract service providers.
  • A detailed capacity analysis, based on global, market wide research on the individual development and manufacturing capacities of various stakeholders in the market. The analysis takes into consideration the average capacities of small, mid-sized, large and very large CMOs, and is based on robust data collection done via both secondary and primary research.
  • Information on other aspects of biopharmaceutical outsourcing, which include the growing number of collaborations, partnerships and investments in facility expansions.
  • Affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry's evolution.

One of the key focus areas of the study was to estimate size of the future opportunity for biopharmaceutical CMOs over the coming decade. In order to provide a detailed future outlook, our projections have been segmented on the basis of commonly outsourced business operations (Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations (FDFs)), types of expression systems and key geographical regions. The base year for the report is 2017, and it provides a detailed market forecast for the period between 2017 and 2027.

The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered both from secondary and primary sources. For the purpose of the study, we invited more than 200 senior stakeholders in the industry to participate in a survey. This enabled us to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. In addition, the opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biotechnologie), Claire Otjes (Assistant Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Dietmar Katinger (CEO, Polymun Scientific), Kevin Daley (Director Pharmaceuticals, Novasep Synthesis), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Raquel Fortunato (CEO, GenIbet Biopharmaceuticals), Sebastian Schuck (Head of Business Development, Wacker Biotech), Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies) and Tim Oldham (CEO, Cell Therapies).

It is worth highlighting that the biopharmaceutical market is characterized by a huge unmet need for adequate manufacturing facilities and expertise. Given the inherent complexities associated with the development of biologics, the aforementioned need is likely to translate into promising business opportunities for CMOs.

Example Highlights:

  • 1. During our research, we came across more than 200 companies offering contract manufacturing services for biopharmaceuticals. These companies possess the capabilities to handle multiple types of biologics; majority of firms offer services related to proteins and peptides (138), antibodies (116), and vaccines (79). Mammalian based manufacturing, the predominant approach, is expected to continue to achieve a relatively higher growth rate in the near future.
  • 2. Developed regions, such as Europe and North America, currently dominate the biopharmaceutical contract manufacturing landscape. In fact, we identified close to 100 biopharmaceutical manufacturing facilities each, belonging to various players, in both Europe and North America. In addition to the developed regions, we observed that a number of prominent global and indigenous players have facilities (60) based in emerging regions of Asia and rest of the world; examples include (in alphabetical order) BioCell, CinnaGen, Cell Therapies, Concord Biotech, EirGenix, GE Healthcare, Kemwell Biopharma, LuinaBio, Meridian Life Science, Piramal Pharma Solutions, and WuXi AppTec (WuXi Biologics).
  • 3. During our research, we identified that 69% of all CMOs offer commercial scale manufacturing services; it is also worth highlighting that 27% of all CMOs offer end-to-end services across all scales of operation; examples of such players include 3P Biopharmaceuticals, Batavia Biosciences, CARBOGEN AMCIS, Cobra Biologics and IDT Biologika.
  • 4. The current global contract biopharmaceutical manufacturing capacity is estimated to be over 3.4 million liters. Established players, such as AbbVie Contract Manufacturing, Celltrion, FUJIFILM Diosynth Biotechnologies, Lonza, Samsung BioLogics and ST Pharm contribute a significant proportion to the overall supply. Having said that, of the over 200 CMOs we evaluated, more than 150 are relatively small or mid-sized companies; such companies are one of the key driving forces behind the heightened pace of biopharmaceutical research and development.
  • 5. Niche and emerging therapeutic classes hold significant promise for biopharmaceutical CMOs. The rapidly growing development pipeline of antibody drug conjugates and bispecific antibodies (100+ molecules each) are likely to translate into tangible growth opportunities. In addition to antibody based therapeutics, cell and gene therapy manufacturing are other opportunities that are likely to unfold in the near future. CMOs such as 3P Biopharmaceuticals, apceth Biopharma, Batavia Biosciences, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, KBI Biopharma, Meridian Life Science, Waisman Biomanufacturing and WuXi AppTec are actively offering services related to these complex biologics.
  • 6. As numerous biopharmaceuticals near patent expiry, a wave of follow-on biologics and biosimilars are anticipated to soon enter the market. As of January 2017, there were over 800 biosimilars under development. Upcoming patent expiries of blockbuster therapies, such as infliximab, trastuzumab and adalimumab, are likely to translate into huge growth opportunities for the biosimilars market, which is likely to result in a surge in the demand for contract services providers.
  • 7. Over 450 deals have been inked in the biopharmaceutical contract manufacturing market in the past decade. Although a significant proportion of these agreements focus on manufacturing (37%), we came across a number of acquisitions / mergers (13%) and specific collaborations (8%) where partner companies have opted to work together in order to significantly expand their respective service portfolios. Several companies have entered into multiple collaborations; these include Lonza (34), CMC Biologics (21), Emergent BioSolutions (20), Charles River Laboratories (19) and Goodwin Biotechnology (18). In addition, multiple players have made significant investments in expanding their existing operations, acquiring new facilities and / or capabilities. We came across more than 150 such instances over the past decade.
  • 8. Driven by increasing global demand and the rapidly expanding biopharmaceutical market, we expect the overall contract manufacturing market in the biopharmaceuticals domain to grow at an annualized rate of 8.7% between 2017 and 2027. The growth is likely to be higher in emerging markets of Asia and rest of the world.

Research Methodology:

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high level view on the current status of the biopharmaceutical contract manufacturing market and where it is headed in the mid-long term.

Chapter 3 is a general introduction to biopharmaceuticals and biopharmaceutical manufacturing processes. The chapter also includes an overview of the various expression systems used for the development of different biologics and biotherapeutic products. It features a brief overview of contract manufacturing and also includes detailed discussion on the need for outsourcing in this field. We have also presented a list of commonly outsourced biomanufacturing activities; the chapter concludes with a discussion on the challenges that are currently associated with the market.

Chapter 4 provides a comprehensive view on the global landscape of biopharmaceutical CMOs. It features an in-depth market review, including regional distribution, analysis by scale of operation, type of biologics manufactured and expression systems. Moreover, the chapter provides information on the production capabilities of CMOs, based on type of bioreactor, mode of operation of bioreactors and fermentation capacity.

Chapter 5 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in the US. Each profile presents a brief overview of the company, its contract service offerings, financial information, manufacturing capabilities and facilities, partnerships, recent developments, and awards and accolades received. The chapter also provides insights on the overall evolution of the biopharmaceutical contract manufacturing market in the US, specifically distributed on the basis of type of service and expression system used, for the period between 2017 and 2027.

Chapter 6 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in the Europe. Each profile presents a brief overview of the company, its contract service offerings, financial information, manufacturing capabilities and facilities, partnerships, recent developments, and awards and accolades received. The chapter also provides insights on the overall evolution of the biopharmaceutical contract manufacturing market in Europe, specifically distributed on the basis of type of service and expression system used, for the period between 2017 and 2027.

Chapter 7 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in Asia and other regions of the world. Each profile presents a brief overview of the company, its contract service offerings, financial information, manufacturing capabilities and facilities, partnerships, recent developments, and awards and accolades received. The chapter also provides insights on the overall evolution of the biopharmaceutical contract manufacturing market in the aforementioned regions, specifically distributed on the basis of type of service and expression system used, for the period between 2017 and 2027.

Chapter 8 focuses on some of the niche segments within the biopharmaceutical industry that are expected to drive the demand for outsourcing in this field. These include ADCs, bispecific antibodies, cell therapies and gene therapies. The chapter provides detailed market overviews, including information on the pipeline, partnerships, investments and the presence of CMOs in each of the aforementioned segments.

Chapter 9 is a case studyfocused on outsourcing of operations related to biosimilars, which represents a major growth opportunity for biopharmaceutical CMOs. It provides an overview of biosimilars and captures information on the various CMOs that are actively involved in this niche market.

Chapter 10 presents an analysis of the recent developments in the biopharmaceutical contract manufacturing market. It provides a detailed list of the various partnerships that have been established in the recent past, along with an overview of other market trends, such as investments and facility expansions.

Chapter 11 features a comprehensive analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of biopharmaceutical products. The results of this analysis were used to gain a more accurate understanding of outsourcing capabilities across different geographies. The analysis represents a holistic view on the supply-side of the market, allowing us to present a highly informed opinion on whether the present capacity will be able to meet the likely future demand.

Chapter 12 presents insights from the survey conducted for this study. We invited over 200 stakeholders involved in the development of different types of gene therapy vectors. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 13 presents a detailed market forecast for the biopharmaceutical contract manufacturing market segmented by type of business (APIs and FDFs). It features an analysis of the future of biopharmaceutical related outsourcing activities for certain specific geographies across the globe, and in terms of the type of expression systems used. To account for the uncertain nature of the market, we have presented three different tracks of the market's evolution, namely the conservative, base and optimistic scenarios.

Chapter 14provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the contract manufacturing market within the biopharmaceutical industry, under a comprehensive SWOT framework.

Chapter 15 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the biopharmaceutical CMOs market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of biopharmaceutical CMOs.

Chapter 16 contains the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the biopharmaceutical contract manufacturing domain. In this study, we spoke to Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biotechnologie), Claire Otjes (Assistant Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Dietmar Katinger (CEO, Polymun Scientific), Kevin Daley (Director Pharmaceuticals, Novasep Synthesis), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Raquel Fortunato (CEO, GenIbet Biopharmaceuticals), Sebastian Schuck (Head of Business Development, Wacker Biotech), Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies) and Tim Oldham (CEO, Cell Therapies).

Chapter 17 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 18 is an appendix that provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Context and Background
  • 3.2. Biopharmaceuticals: An Overview
  • 3.3. Biopharmaceuticals: Manufacturing Process
    • 3.3.1. Types of Expression Systems
      • 3.3.1.1. Bacterial Expression Systems
      • 3.3.1.2. Yeast Expression Systems
      • 3.3.1.3. Insect Expression Systems
      • 3.3.1.4. Plant Expression Systems
      • 3.3.1.5. Mammalian Expression Systems
    • 3.3.2. Processing Steps
      • 3.3.2.1. Upstream Processing
      • 3.3.3.2. Downstream Processing
  • 3.4. Contract Manufacturing: An Overview
  • 3.5. The Need for Outsourcing in the Biopharmaceutical Industry
  • 3.6. Biopharmaceutical Contract Manufacturing: Commonly Outsourced Operations
  • 3.7. Biopharmaceutical Contract Manufacturing: Selecting a CMO Partner
  • 3.8. Biopharmaceutical Contract Manufacturing: Associated Risks and Challenges

4. COMPETITIVE LANDSCAPE

  • 4.1. Chapter Overview
    • 4.1.1. Geographical Presence of Biopharmaceutical CMOs
    • 4.1.2. Analysis by Types of Biologics
    • 4.1.3. Analysis by Scale of Operation
    • 4.1.4. Analysis by Expression Systems
    • 4.1.5. Analysis by Types of Bioreactors and Modes of Operation
    • 4.1.6. Analysis by Manufacturing Capacity
    • 4.1.7. Analysis by Packaging Form

5. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA

  • 5.1. Chapter Overview
  • 5.2. Biopharmaceutical Outsourcing in North America: Regulatory Scenario
    • 5.2.1. Impact of Current Political Situation
  • 5.3. Leading Biopharmaceutical CMOs in North America
    • 5.3.1. AMRI
      • 5.3.1.1. Company Overview
      • 5.3.1.2. Services Portfolio
        • 5.3.1.2.1. Regulatory Support and Quality Assurance
        • 5.3.1.2.2. Biomanufacturing Services
      • 5.3.1.3. Financial Information
      • 5.3.1.4. Manufacturing Facilities
      • 5.3.1.5. Partnerships
      • 5.3.1.6. Recent Developments
      • 5.3.1.7. Awards and Accolades
      • 5.3.1.8. Future Outlook
    • 5.3.2. Baxter BioPharma Solutions
      • 5.3.2.1. Company Overview
      • 5.3.2.2. Services Portfolio
        • 5.3.2.2.1. Biologics Related Services
        • 5.3.2.2.2. Vaccine Related Services
        • 5.3.2.2.3. Regulatory Support
      • 5.3.2.3. Financial Information
      • 5.3.2.4. Manufacturing Facilities
      • 5.3.2.5. Partnerships
      • 5.3.2.6. Recent Developments
      • 5.3.2.7. Awards and Accolades
    • 5.3.3. Catalent
      • 5.3.3.1. Company Overview
      • 5.3.3.2. Services Portfolio
        • 5.3.3.2.1. Cell Line Development
        • 5.3.3.2.2. Manufacturing (Biomanufacturing)
        • 5.3.3.2.3. ADCs and Bioconjugates
        • 5.3.3.2.4. Biosimilars
        • 5.3.3.2.5. Analytical Services
        • 5.3.3.2.6. Clinical Supply Services
        • 5.3.3.2.7. Regulatory Support
        • 5.3.3.3. Financial Information
      • 5.3.3.4. Manufacturing Facilities
      • 5.3.3.5. Partnerships
      • 5.3.3.6. Recent Developments
      • 5.3.3.7. Awards and Accolades
      • 5.3.3.8. Future Outlook
    • 5.3.4. Cytovance Biologics
      • 5.3.4.1. Company Overview
      • 5.3.4.2. Services Portfolio
        • 5.3.4.2.1. R&D Services
        • 5.3.4.2.2. Manufacturing Services
        • 5.3.4.2.3. Purification and Fill/Finish
      • 5.3.4.3. Manufacturing Facilities
      • 5.3.4.4. Partnerships
      • 5.3.4.5. Recent Developments
      • 5.3.4.6. Awards and Accolades
    • 5.3.5. Patheon
      • 5.3.5.1. Company Overview
      • 5.3.5.2. Services Portfolio
        • 5.3.5.2.1. Biologics
        • 5.3.5.2.2. Small Molecules
        • 5.3.5.2.3. Supply Chain Management
      • 5.3.5.3. Financial Information
      • 5.3.5.4. Manufacturing Facilities
      • 5.3.5.5. Partnerships and Acquisitions
      • 5.3.5.6. Recent Developments
      • 5.3.5.7. Awards and Accolades
  • 5.4. Biopharmaceutical Contract Manufacturing in North America: Sub-Market Forecast, 2017-2027
    • 5.4.1. Biopharmaceutical Contract Manufacturing in North America: Distribution by Type of Business Operation, 2017-2027
    • 5.4.2. Biopharmaceutical Contract Manufacturing in North America: Distribution by Expression Systems, 2017-2027

6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE

  • 6.1. Chapter Overview
  • 6.2. Biopharmaceutical Outsourcing in Europe: Regulatory Scenario
  • 6.3. Leading Biopharmaceutical CMOs in Europe
    • 6.3.1. 3P Biopharmaceuticals
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Services Portfolio
      • 6.3.1.3. Manufacturing Facilities
      • 6.3.1.4. Partnerships
      • 6.3.1.5. Recent Developments
      • 6.3.1.6. Awards and Accolades
    • 6.3.2. Boehringer Ingelheim BioXcellence
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Services Portfolio
      • 6.3.2.3. Financial Information
      • 6.3.2.4. Manufacturing Facilities
      • 6.3.2.5. Partnerships
      • 6.3.2.6. Recent Developments
      • 6.3.2.7. Awards and Accolades
    • 6.3.3. Celonic
      • 6.3.3.1. Company Overview
      • 6.3.3.2. Services Portfolio
      • 6.3.3.3. Manufacturing Facilities
      • 6.3.3.4. Partnerships
      • 6.3.3.5. Recent Developments
    • 6.3.4. FUJIFILM Diosynth Biotechnologies
      • 6.3.4.1. Company Overview
      • 6.3.4.2. Services Portfolio
      • 6.3.4.3. Financial Information
      • 6.3.4.4. Manufacturing Facilities
      • 6.3.4.5. Partnerships
      • 6.3.4.6. Recent Developments
    • 6.3.5. LFB Biopharma
      • 6.3.5.1. Company Overview
      • 6.3.5.2. Services Portfolio
      • 6.3.5.3. Financial Information
      • 6.3.5.4. Manufacturing Facilities
      • 6.3.5.5. Partnerships
      • 6.3.5.6. Recent Developments
    • 6.3.6. Lonza
      • 6.3.6.1. Company Overview
      • 6.3.6.2. Services Portfolio
      • 6.3.6.3. Financial Information
      • 6.3.6.4. Manufacturing Facilities
      • 6.3.6.5. Partnerships
      • 6.3.6.6. Recent Developments
    • 6.3.7. Menarini Biotech
      • 6.3.7.1. Company Overview
      • 6.3.7.2. Services Portfolio
      • 6.3.7.3. Partnerships
    • 6.3.8. Novasep
      • 6.3.8.1. Company Overview
      • 6.3.8.2. Services Portfolio
      • 6.3.8.3. Financial Information
      • 6.3.8.4. Manufacturing Facilities
      • 6.3.8.5. Partnerships
      • 6.3.8.6. Recent Developments
    • 6.3.9. Rentschler Biotechnologie
      • 6.3.9.1. Company Overview
      • 6.3.9.2. Services Portfolio
      • 6.3.9.3. Manufacturing Facilities
      • 6.3.9.4. Partnerships
      • 6.3.9.5. Recent Developments
  • 6.4. Biopharmaceutical Contract Manufacturing in Europe: Sub-Market Forecast, 2017-2027
    • 6.4.1. Biopharmaceutical Contract Manufacturing in Europe: Distribution by Type of Business Operation, 2017-2027
    • 6.4.2. Biopharmaceutical Contract Manufacturing in Europe: Distribution by Expression Systems, 2017-2027

7. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA AND THE REST OF THE WORLD

  • 7.1. Chapter Overview
  • 7.2. Biopharmaceutical Contract Manufacturing in China
    • 7.2.1. Biopharmaceutical Outsourcing in China: Regulatory Scenario
    • 7.2.2. Challenges Faced by CMOs in China
  • 7.3. Leading Biopharmaceutical CMOs in China
    • 7.3.1. Autotek Bio
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Services Portfolio
      • 7.3.1.3. Manufacturing Facilities
    • 7.3.2. WuXi AppTec
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Services Portfolio
      • 7.3.2.3. Financial Information
      • 7.3.2.4. Manufacturing Facilities
      • 7.3.2.5. Partnerships
      • 7.3.2.6. Recent Developments
  • 7.4. Biopharmaceutical Contract Manufacturing in China: Sub-Market Forecast, 2017-2027
    • 7.4.1. Biopharmaceutical Contract Manufacturing in China: Distribution by Type of Business Operation, 2017-2027
    • 7.4.2. Biopharmaceutical Contract Manufacturing in China: Distribution by Expression Systems, 2017-2027
  • 7.5. Biopharmaceutical Contract Manufacturing in India
    • 7.5.1. Biopharmaceutical Outsourcing in India: Regulatory Scenario
    • 7.5.2. Challenges Faced by CMOs in India
  • 7.6. Leading Biopharmaceutical CMOs in India
    • 7.6.1. Intas Pharmaceuticals
      • 7.6.1.1. Company Overview
      • 7.6.1.2. Services Portfolio
      • 7.6.1.3. Financial Information
      • 7.6.1.4. Manufacturing Facilities
      • 7.6.1.5. Partnerships
    • 7.6.2. Kemwell Biopharma
      • 7.6.2.1. Company Overview
      • 7.6.2.2. Services Portfolio
      • 7.6.2.3. Manufacturing Facilities
      • 7.6.2.4. Partnerships
      • 7.6.2.5. Recent Developments
    • 7.6.3. Piramal Pharma Solutions
      • 7.6.3.1. Company Overview
      • 7.6.3.2. Services Portfolio
      • 7.6.3.3. Financial Information
      • 7.6.3.4. Manufacturing Facilities
      • 7.6.3.5. Partnerships
      • 7.6.3.6. Recent Developments
    • 7.6.4. Shashun Pharma
      • 7.6.4.1. Company Overview
      • 7.6.4.2. Services Portfolio
      • 7.6.4.3. Financial Information
      • 7.6.4.4. Manufacturing Facilities
      • 7.6.4.5. Partnerships
    • 7.6.5. Syngene
      • 7.6.5.1. Company Overview
      • 7.6.5.2. Services Portfolio
      • 7.6.5.3. Financial Information
      • 7.6.5.4. Manufacturing Facilities
      • 7.6.5.5. Partnerships
  • 7.7. Biopharmaceutical Contract Manufacturing in India: Sub-Market Forecast, 2017-2027
    • 7.7.1. Biopharmaceutical Contract Manufacturing in India: Distribution by Type of Business Operation, 2017-2027
    • 7.7.2. Biopharmaceutical Contract Manufacturing in India: Distribution by Expression Systems, 2017-2027
  • 7.8. Biopharmaceutical Contract Manufacturing in Japan
    • 7.8.1. Biopharmaceutical Outsourcing in Japan: Regulatory Scenario
    • 7.8.2. Challenges Faced by CMOs in Japan
  • 7.9. Leading Biopharmaceutical CMOs in Japan
    • 7.9.1. Asahi Glass
      • 7.9.1.1. Company Overview
      • 7.9.1.2. Services Portfolio
      • 7.9.1.3. Financial Information
      • 7.9.1.4. Manufacturing Facilities
      • 7.9.1.5. Partnerships
  • 7.10. Biopharmaceutical Contract Manufacturing in Japan: Sub-Market Forecast, 2017-2027
    • 7.10.1. Biopharmaceutical Contract Manufacturing in Japan: Distribution by Type of Business Operation, 2017-2027
    • 7.10.2. Biopharmaceutical Contract Manufacturing in Japan: Distribution by Expression Systems, 2017-2027
  • 7.11. Biopharmaceutical Contract Manufacturing in South Korea
    • 7.11.1. Biopharmaceutical Outsourcing in South Korea: Regulatory Scenario
    • 7.11.2. Challenges Faced by CMOs in South Korea
  • 7.12. Leading Biopharmaceutical CMOs in South Korea
    • 7.12.1. DMBio
      • 7.12.1.1. Company Overview
      • 7.12.1.2. Services Portfolio
      • 7.12.1.3. Manufacturing Facilities
      • 7.12.1.4. Recent Developments
    • 7.12.2. Samsung BioLogics
      • 7.12.2.1. Company Overview
      • 7.12.2.2. Services Portfolio
      • 7.12.2.3. Financial Information
      • 7.12.2.4. Manufacturing Facilities
      • 7.12.2.5. Partnerships
      • 7.12.2.6. Recent Developments
  • 7.13. Biopharmaceutical Contract Manufacturing in South Korea: Sub-Market Forecast, 2017-2027
    • 7.13.1. Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Type of Business Operation, 2017-2027
    • 7.13.2. Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Expression Systems, 2017-2027
  • 7.14. Biopharmaceutical Contract Manufacturing in Australia
    • 7.14.1. Biopharmaceutical Outsourcing in Australia: Regulatory Scenario
    • 7.14.2. Challenges Faced by CMOs in Australia
  • 7.15. Leading Biopharmaceutical CMOs in Australia
    • 7.15.1. Cell Therapies
      • 7.15.1.1. Company Overview
      • 7.15.1.2. Services Portfolio
      • 7.15.1.3. Manufacturing Facilities
      • 7.15.1.4. Partnerships
      • 7.15.1.5. Recent Developments
    • 7.15.2. LuinaBio
      • 7.15.2.1. Company Overview
      • 7.15.2.2. Services Portfolio
      • 7.15.2.3. Manufacturing Facilities
      • 7.15.2.4. Partnerships

8. NICHE SECTORS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING

  • 8.1. Chapter Overview
  • 8.2. Antibody Drug Conjugates
    • 8.2.1. Introduction
      • 8.2.1.1. Manufacturing Process
      • 8.2.1.2. Key Technologies and Technology Providers
    • 8.2.2. Pipeline Analysis
      • 8.2.2.1. ADC Pipeline: Marketed and Clinical Molecules
      • 8.2.2.2. ADC Pipeline: Preclinical and Discovery Stage Molecules
    • 8.2.3. In-house Manufacturing Scenario
      • 8.2.3.1. Challenges Faced by ADC Manufacturers
    • 8.2.4. Contract Manufacturing Scenario
      • 8.2.4.1. Types of Contract Services Providers
        • 8.2.4.1.1. ADC CMOs: Companies Providing Linker Production Services
        • 8.2.4.1.2. ADC CMOs: Companies Providing HPAPI / Cytotoxic Drug Production Services
        • 8.2.4.1.3. ADC CMOs: Companies Providing Conjugation Services
        • 8.2.4.1.4. ADC CMOs: Full Services Providers
    • 8.2.5. Key Drivers of the Contract Manufacturing Market for ADCs
      • 8.2.5.1. Emergence of Startups
      • 8.2.5.2. Investments and Facility Expansions
      • 8.2.5.3. Partnerships and Collaborations
  • 8.3. Bispecific Antibodies
    • 8.3.1. Introduction
      • 8.3.1.1. The Bispecific Advantage
      • 8.3.1.2. Classification of Bispecific Antibodies
    • 8.3.2. Pipeline Analysis
    • 8.3.3. Bispecific Antibody Based Technology Providers
    • 8.3.4. Contract Manufacturing Scenario
  • 8.4. Cell Therapy
    • 8.4.1. Introduction
    • 8.4.2. Current Market Landscape
    • 8.4.3. Cell Therapy Manufacturing
      • 8.4.3.1. Cell Therapy Manufacturing: Key Challenges and Growth Drivers
    • 8.4.4. Types of Manufacturers
    • 8.4.2. Contract Manufacturing Scenario
  • 8.5. Gene Therapy
    • 8.5.1. Introduction
    • 8.5.2. Pipeline Analysis
    • 8.5.3. Contract Manufacturing Scenario

9. CASE STUDY: OUTSOURCING OF BIOSIMILARS

  • 9.1. Chapter Overview
  • 9.2. Biosimilars: An Introduction
  • 9.3. Biosimilars: Need for Outsourcing of Development and Manufacturing Operations
  • 9.4. Impact of Biosimilars on the Global Contract Manufacturing Market
    • 9.4.1. Pipeline Analysis
    • 9.4.2. Regional Trends
    • 9.4.3. Contract Services Providers
  • 9.5. Biosimilars: Challenges Associated with Outsourcing

10. RECENT DEVELOPMENTS

  • 10.1. Chapter Overview
  • 10.2. Biopharmaceutical Contract Manufacturing Market: Partnerships
    • 10.2.1. Biopharmaceutical Contract Manufacturing Market: Growing Trend of Partnerships
    • 10.2.2. Biopharmaceutical Contract Manufacturing Market: Analysis by Type of Partnership
  • 10.3. Biopharmaceutical Contract Manufacturing Market: Recent Developments
    • 10.3.1. Biopharmaceutical Contract Manufacturing Market: Growing Trend of Recent Developments
    • 10.3.2. Biopharmaceutical Contract Manufacturing Market: Analysis by Type of Recent Development
  • 10.4. Biopharmaceutical Contract Manufacturing Market: Funding Instances
  • 10.5. Biopharmaceutical Contract Manufacturing Market: Technological Advances
    • 10.5.1. Adoption of Single-use Technologies
    • 10.5.2. Process Analytical Technologies
    • 10.5.3. Continuous Processing
    • 10.5.4. Quality by Design in Bio-processing

11. CAPACITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Assumptions and Methodology
  • 11.3. Biopharmaceutical CMOs: Global Production Capacity
    • 11.3.1. Analysis by Region
    • 11.3.2. Analysis by Expression Systems
  • 11.4. Conclusion

12. SURVEY ANALYSIS

  • 12.1. Chapter Overview
  • 12.1.1. Overview of Respondents
  • 12.1.2. Designation of Respondents
  • 12.2. Biologics Manufacturing Expertise
  • 12.3. Scale of Manufacturing
  • 12.4. Location of Production Facilities
  • 12.5. Types of Expression Systems
  • 12.6. Types of Bioreactors
  • 12.7. Modes of Operation of Bioreactors

13. OPPORTUNITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology
  • 13.3. Overall Biopharmaceutical Contract Manufacturing Market, 2017-2027
    • 13.3.1. Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2017-2027
    • 13.3.2. Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2017-2027
  • 13.4. Biopharmaceutical Contract Manufacturing Market, 2017-2027: Analysis by Expression Systems
  • 13.5. Biopharmaceutical Contract Manufacturing Market, 2017-2027: Regional Distribution

14. SWOT ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Strengths
  • 14.3. Weaknesses
  • 14.4. Opportunities
  • 14.5. Threats
  • 14.6. Conclusion

15. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET

  • 15.1. Chapter Overview
  • 15.2. Significant Growth in Outsourcing Activities
  • 15.3. Evident Shift from One-time Contracts to Strategic Partnerships
  • 15.4. New Technologies and Focus on Innovation to Support Further Growth in this Domain
  • 15.5. Focus on Niche Therapeutic Areas to Sustain Growth
  • 15.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
  • 15.7. CMOs are Increasingly Expanding their Capabilities and Expertise in Order to become One Stop Shops
  • 15.8. Offshoring of Outsourcing Activities to Maximize Profits and Expand Existing Capacities
  • 15.9. Growing Demand for Biologics and Biosimilars to Influence Financial Inflow and Outsourcing Budgets
  • 15.10. The Need for Humanized Products to Drive the Growth of Mammalian Expression Technologies
  • 15.11. Despite the Positive Future Outlook, There are a Number of Challenges Faced by both Sponsors and Service Providers
  • 15.12. Concluding Remarks

16. INTERVIEW TRANSCRIPTS

  • 16.1. Chapter Overview
  • 16.2. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
  • 16.3. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
  • 16.4. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
  • 16.5. Dietmar Katinger, CEO, Polymun Scientific
  • 16.6. Kevin Daley, Director Pharmaceuticals, Novasep Synthesis
  • 16.7. Mark Wright, Site Lead, Grangemouth, Piramal Healthcare
  • 16.8. Raquel Fortunato, CEO, GenIbet Biopharmaceuticals
  • 16.9. Sebastian Schuck, Head of Business Development, Wacker Biotech
  • 16.10. Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
  • 16.11. Tim Oldham, CEO, Cell Therapies
  • 16.12. Anonymous

17. APPENDIX I TABULATED DATA

18. APPENDIX II LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 3.1: Types of Third Party Service Providers
  • Figure 3.2: Biopharmaceutical Contract Manufacturing: Commonly Outsourced Operations
  • Figure 4.1: Biopharmaceutical CMOs: Geographical Distribution of Facilities
  • Figure 4.2: Biopharmaceutical CMOs: Geographical Distribution of Facilities by Major Regions
  • Figure 4.3: Biopharmaceutical CMOs: Distribution by Types of Biologics
  • Figure 4.4: Biopharmaceutical CMOs: Distribution by Scale of Operation
  • Figure 4.5: Biopharmaceutical CMOs: Distribution by Expression Systems
  • Figure 4.6: Biopharmaceutical CMOs: Distribution by Types of Bioreactors
  • Figure 4.7: Biopharmaceutical CMOs: Distribution by Modes of Operation of Bioreactors
  • Figure 5.1: Biopharmaceutical Contract Manufacturing in the US: Growth Drivers and Challenges
  • Figure 5.2: AMRI: Services Portfolio
  • Figure 5.3: AMRI Annual Revenues, FY 2012-FY 2016 (USD Million)
  • Figure 5.4: AMRI: Revenues by Business Divisions, FY 2016 (USD Million)
  • Figure 5.5: Baxter International: Annual Revenues, FY 2012-FY 2016 (USD Million)
  • Figure 5.6: Catalent: Services Portfolio
  • Figure 5.7: Catalent: Annual Revenues, FY 2012-FY 2016 (USD Million)
  • Figure 5.8: Catalent: Revenues by Business Divisions, FY 2016 (USD million)
  • Figure 5.9: Cytovance: Services Portfolio
  • Figure 5.10: Patheon: Services Portfolio
  • Figure 5.11: Patheon Services and Solutions: Biologics
  • Figure 5.12: Patheon Services and Solutions: Small Molecules
  • Figure 5.13: Patheon: Annual Revenues, FY 2012-Q1 2017 (USD Million)
  • Figure 5.14: Patheon: Revenues by Business Divisions, FY 2016 (USD Million)
  • Figure 5.15: Biopharmaceutical Contract Manufacturing in the US: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
  • Figure 5.16: Biopharmaceutical Contract Manufacturing in the US: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
  • Figure 6.1: Biopharmaceutical Contract Manufacturing in Europe: Growth Drivers and Challenges
  • Figure 6.2: 3P Biopharmaceuticals: Services Portfolio
  • Figure 6.3: Boehringer Ingelheim BioXcellence: Services Portfolio
  • Figure 6.4: Boehringer Ingelheim: Annual Revenues, FY 2012-FY 2016 (EUR Million)
  • Figure 6.5: Boehringer Ingelheim: Revenues by Business Divisions, FY 2016 (EUR Million)
  • Figure 6.6: Celonic: Services Portfolio
  • Figure 6.7: FUJIFILM Diosynth Biotechnologies: Services Portfolio
  • Figure 6.8: FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2012- Q1-Q3 2017 (JPY Billion)
  • Figure 6.9: FUJIFILM Holdings: Revenues by Business Divisions, FY 2016 (JPY Billion)
  • Figure 6.10: LFB Group: Services Portfolio
  • Figure 6.11: CELLforCURE: Services Portfolio
  • Figure 6.12: LFB Biomanufacturing Services: Services Portfolio
  • Figure 6.13: LFB Group: Annual Revenues, FY 2012-FY 2016 (EUR Million)
  • Figure 6.14: LFB Group: Revenues by Therapeutic Area and Services, FY 2016 (EUR Million)
  • Figure 6.15: Lonza: Services Portfolio
  • Figure 6.16: Lonza: Annual Revenues, FY 2012-FY 2016 (CHF Million)
  • Figure 6.17: Lonza: Revenues by Business Divisions, FY 2016 (CHF Million)
  • Figure 6.18: Menarini Biotech: Services Portfolio
  • Figure 6.19: Novasep: Services Portfolio
  • Figure 6.20: Rentschler Biotechnologie: Services Portfolio
  • Figure 6.21: Biopharmaceutical Contract Manufacturing in Europe: Distribution by Country, Base Scenario, 2017-2027 (USD Billion)
  • Figure 6.22: Biopharmaceutical Contract Manufacturing in Europe: Distribution by Type of: Business Operation, Base Scenario, 2017-2027 (USD Billion)
  • Figure 6.23: Biopharmaceutical Contract Manufacturing in Europe: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
  • Figure 7.1: Biopharmaceutical Contract Manufacturing in China: Growth Drivers and Challenges
  • Figure 7.2: Autotek Bio: Services Portfolio
  • Figure 7.3: Autotek Bio: DisposUp® Technology
  • Figure 7.4: WuXi Biologics: Services Portfolio
  • Figure 7.5: WuXi Biologics: Antibody Discovery Procedure
  • Figure 7.6: Biopharmaceutical Contract Manufacturing in China: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
  • Figure 7.7: Biopharmaceutical Contract Manufacturing in China: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
  • Figure 7.8: Biopharmaceutical Contract Manufacturing in India: Growth Drivers and Challenges
  • Figure 7.9: Intas Pharmaceuticals: Revenues from Operations, FY 2012-FY 2016 (INR Million)
  • Figure 7.10: Piramal Pharma Solutions: Annual Revenues, FY 2012-FY 2016 (INR Million)
  • Figure 7.11: Shasun Pharma: Revenues by Geography, FY 2015-FY 2016 (INR Billion)
  • Figure 7.12: Syngene: Services Portfolio
  • Figure 7.13: Syngene: Annual Revenues, FY 2012-Q1 2017 (INR Million)
  • Figure 7.14: Biopharmaceutical Contract Manufacturing in India: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
  • Figure 7.15: Biopharmaceutical Contract Manufacturing in India: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
  • Figure 7.16: Asahi Glass: Services Portfolio
  • Figure 7.17: Asahi Glass: Annual Revenues, FY 2012-Q1 2017 (JPY Million)
  • Figure 7.18: Biopharmaceutical Contract Manufacturing in Japan: Distribution by Type of: Business Operation, Base Scenario, 2017-2027 (USD Billion)
  • Figure 7.19: Biopharmaceutical Contract Manufacturing in Japan: Distribution by: Expression Systems, Base Scenario, 2017-2027 (USD Billion)
  • Figure 7.20: DMBio: Services Portfolio
  • Figure 7.21: DMBio: Manufacturing Services
  • Figure 7.22: Samsung BioLogics: Services Portfolio
  • Figure 7.23: Samsung BioLogics: Annual Revenues from CMO Operations, FY 2013-Q1 2017 (KRW Billion)
  • Figure 7.24: Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
  • Figure 7.25: Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
  • Figure 7.26: Cell Therapies: Cell Therapy Services
  • Figure 7.27: Luina Bio: Services Portfolio
  • Figure 8.1: Bispecific Antibodies Pipeline: Distribution by Phase of Development
  • Figure 8.2: Cell Therapy Manufacturing: Key Steps
  • Figure 8.3: Cell Therapy: Key Challenges and Growth Drivers
  • Figure 8.4: Cell Therapy Manufacturing: Types of Manufacturers
  • Figure 8.5: Gene Therapy Pipeline: Distribution by Phase of Development
  • Figure 8.6: Gene Therapy Contract Manufacturers: Distribution by Scale of Operation
  • Figure 8.7: Gene Therapy Contract Manufacturers: Distribution by Location
  • Figure 9.1: Global Biosimilars Pipeline: Distribution by Phase of Development
  • Figure 9.2: Global Biosimilars Pipeline: Distribution by Phase of Development and Product Category
  • Figure 9.3: Global Biosimilars Pipeline: Distribution by Phase of Development and Geography
  • Figure 10.1: Biopharmaceutical Contract Manufacturing Market: Cumulative Trend of Partnerships
  • Figure 10.2: Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Partnership
  • Figure 10.3: Biopharmaceutical Contract Manufacturing Market: Cumulative Trend of Recent Developments
  • Figure 10.4: Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Recent Development
  • Figure 10.5: Process Analytical Technologies: Key Advantages
  • Figure 10.6: Continuous Processing: Key Advantages
  • Figure 11.1: Capacity Analysis: Global Contract Biomanufacturing Capacity by Size of CMOs
  • Figure 11.2: Capacity Analysis: Regional Distribution of Biopharmaceutical CMOs (Small and Mid-sized CMOs)
  • Figure 11.3: Capacity Analysis: Regional Production Capacity of Biopharmaceutical CMOs (Small and Mid-sized CMOs)
  • Figure 11.4: Capacity Analysis: Regional Contract Biomanufacturing Capacity (Small and Mid-sized CMOs)
  • Figure 11.5: Capacity Analysis: Percentage Distribution by Expression Systems Used
  • Figure 12.1: Survey Analysis: Distribution of Respondents by Company Type
  • Figure 12.2: Survey Analysis: Distribution of Respondents by Location of Headquarters
  • Figure 12.3: Survey Analysis: Distribution of Respondents by Designation
  • Figure 12.4: Survey Analysis: Distribution by Biologics Manufacturing Expertise
  • Figure 12.5: Survey Analysis: Distribution by Scale of Manufacturing
  • Figure 12.6: Survey Analysis: Distribution by Location of Production Facilities
  • Figure 12.7: Survey Analysis: Distribution by Types of Expression Systems
  • Figure 12.8: Survey Analysis: Distribution by Types of Bioreactors
  • Figure 12.9: Survey Analysis: Distribution by Modes of Operation of Bioreactors
  • Figure 13.1: Biopharmaceutical Contract Manufacturing Market: Share of Contract Manufacturers
  • Figure 13.2: Global Biopharmaceutical Contract Manufacturing Market, 2017-2027: Base Scenario (USD Billion)
  • Figure 13.3: Global Biopharmaceutical Contract Manufacturing Market for API, 2017-2027: Base Scenario (USD Billion)
  • Figure 13.4: Global Biopharmaceutical Contract Manufacturing Market for FDF, 2017-2027: Base Scenario (USD Billion)
  • Figure 13.5: Distribution of Global Biopharmaceutical Contract Manufacturing Market by Expression Systems, 2017-2027: Base Scenario (USD Billion)
  • Figure 13.6: Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017-2027: Base Scenario (USD Billion)
  • Figure 14.1: Global Biopharmaceuticals Market: Number of FDA Approvals by Year, 2002- 2016

List of Tables:

  • Table 4.1: Biopharmaceutical CMOs: Geographical Presence
  • Table 4.2: Biopharmaceutical CMOs: Types of Biologics
  • Table 4.3: Biopharmaceutical CMOs: Scale of Operation
  • Table 4.4: Biopharmaceutical CMOs: Types of Expression Systems
  • Table 4.5: Biopharmaceutical CMOs: Types of Bioreactors
  • Table 4.6: Biopharmaceutical CMOs: Modes of Operation
  • Table 4.7: Biopharmaceutical CMOs: Contract Biomanufacturing Capacity
  • Table 4.8: Biopharmaceutical CMOs: Types of Packaging Forms
  • Table 5.1: Catalent: Biopharmaceutical Facilities
  • Table 5.2: Patheon: Biopharmaceutical Facilities
  • Table 6.1: FDA Quality Agreement versus EMA cGMP Regulations: A Comparative Analysis
  • Table 6.2: Boehringer Ingelheim BioXcellence: Biopharmaceutical Facilities
  • Table 6.3: Celonic: Biopharmaceutical Facilities
  • Table 6.4: FUJIFILM Diosynth Biotechnologies: Biomanufacturing Capabilities
  • Table 6.5: Lonza: Biopharmaceutical Facilities
  • Table 7.1: Intas Pharmaceuticals: Biopharmaceutical Facilities
  • Table 7.2: Kemwell Biopharma: Biopharmaceutical Facilities
  • Table 7.3: Piramal Pharma Solutions: Biopharmaceutical Facilities
  • Table 7.4: Shasun Pharma: Biopharmaceutical Facilities
  • Table 7.5: Samsung BioLogics: Biopharmaceutical Facilities
  • Table 8.1: ADC Pipeline: Marketed and Clinical Molecules
  • Table 8.2: ADC Pipeline: Preclinical and Discovery Stage Molecules
  • Table 8.3: ADC Contract Manufacturers: Overview of Capabilities
  • Table 8.4: ADC Contract Manufacturers: Conjugation Services Providers
  • Table 8.5: ADC Contract Manufacturers: Full Services CMOs
  • Table 8.6: Bispecific Antibodies Pipeline
  • Table 8.7: Bispecific Antibody Technologies and Technology Providers
  • Table 8.8: Cell Therapies: Applications
  • Table 8.9: Cell Therapies: Commercialized Products
  • Table 8.10: Cell Therapy Manufacturing: Assessment Strategies for Different Manufacturing Processes
  • Table 8.11: Cell Therapy Contract Manufacturers
  • Table 8.12: Gene Therapy Contract Manufacturers
  • Table 9.1: Contract Services Providers for Biosimilars
  • Table 10.1: Biopharmaceutical Contract Manufacturing Market: Partnerships
  • Table 10.2: Biopharmaceutical Contract Manufacturing Market: Recent Developments
  • Table 10.2: Biopharmaceutical Contract Manufacturing Market: Funding Instances
  • Table 11.1: Capacity Analysis: CMO Size Adjustments based on Capacity
  • Table 11.2: Capacity Analysis: CMO Size Adjustments based on Employee Base
  • Table 11.3: Capacity Analysis: Average Capacity per Category
  • Table 11.4: Capacity Analysis: Global Contract Biomanufacturing Capacity
  • Table 11.4: Capacity Analysis: Regional Contract Biomanufacturing Capacity (Small and Mid-sized CMOs)
  • Table 12.1: Survey Analysis: Overview of Respondents
  • Table 12.2: Survey Analysis: Distribution of Respondents by Designation
  • Table 12.3: Survey Analysis: Biologics Manufacturing Expertise
  • Table 12.4: Survey Analysis: Scale of Manufacturing
  • Table 12.5: Survey Analysis: Location of Production Facilities
  • Table 12.6: Survey Analysis: Types of Expression Systems
  • Table 12.7: Survey Analysis: Types of Bioreactors
  • Table 12.8: Survey Analysis: Modes of Operation of Bioreactors
  • Table 14.1: Biopharmaceutical Contract Manufacturing Market: SWOT Analysis
  • Table 14.2: Global Biopharmaceuticals Market: Patent Approval and Expiry Details of Best- selling Biologics
  • Table 17.1: Biopharmaceutical CMOs: Geographical Distribution of Facilities
  • Table 17.2: Biopharmaceutical CMOs: Geographical Distribution of Facilities by Major Regions
  • Table 17.3: Biopharmaceutical CMOs: Distribution by Types of Biologics
  • Table 17.4: Biopharmaceutical CMOs: Distribution by Scale of Operation
  • Table 17.5: Biopharmaceutical CMOs: Distribution by Expression Systems
  • Table 17.6: Biopharmaceutical CMOs: Distribution by Types of Bioreactors
  • Table 17.7: Biopharmaceutical CMOs: Distribution by Modes of Operation
  • Table 17.8: AMRI Annual Revenues, FY 2012-Q1 2017 (USD Million)
  • Table 17.9: AMRI: Revenues by Business Segments, FY 2016 (USD Million)
  • Table 17.10: Baxter International: Revenues, FY 2012 - Q1 2017 (USD Million)
  • Table 17.11: Catalent: Revenues, FY 2012 - Q1-Q3 2017 (USD Million)
  • Table 17.12: Catalent: Revenues by Business Divisions, FY 2016 (USD Million)
  • Table 17.13: Patheon: Annual Revenues, FY 2012 - Q1 2017 (USD Million)
  • Table 17.14: Patheon: Revenues by Business Segments, FY 2016 (USD Million)
  • Table 17.15: Biopharmaceutical Contract Manufacturing in North America: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
  • Table 17.16: Biopharmaceutical Contract Manufacturing in North America: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
  • Table 17.17: Biopharmaceutical Contract Manufacturing in North America: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
  • Table 17.18: Biopharmaceutical Contract Manufacturing in the US: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
  • Table 17.19: Biopharmaceutical Contract Manufacturing in the US: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
  • Table 17.20: Biopharmaceutical Contract Manufacturing in the US: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
  • Table 17.21: Boehringer Ingelheim: Annual Revenues, FY 2012 - FY 2016 (EUR Million)
  • Table 17.22: Boehringer Ingelheim: Revenues by Business Divisions, FY 2016 (EUR Million)
  • Table 17.23: FUJIFILM Group: Revenues, FY 2012 - Q1-Q3 2017 (JPY Billion)
  • Table 17.24: FUJIFILM Holdings: Revenue by Business Divisions, FY 2016 (JPY Billion)
  • Table 17.25: LFB Group: Annual Revenues, FY 2012 - FY 2015 (EUR Million)
  • Table 17.26: LFB Group: Revenues by Therapeutic Area and Services, FY 2015 (EUR Million)
  • Table 17.27: Lonza: Annual Revenues, FY 2012 - FY2016 (CHF Million)
  • Table 17.28: Lonza: Revenues by Business Divisions, 2016 (CHF Million)
  • Table 17.29: Biopharmaceutical Contract Manufacturing in Europe: Distribution by Country, Conservative Scenario, 2017-2027 (USD Billion)
  • Table 17.30: Biopharmaceutical Contract Manufacturing in Europe: Distribution by Country, Base Scenario, 2017-2027 (USD Billion)
  • Table 17.31: Biopharmaceutical Contract Manufacturing in Europe: Distribution by Country, Optimistic Scenario, 2017-2027 (USD Billion)
  • Table 17.32: Biopharmaceutical Contract Manufacturing in Europe: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
  • Table 17.33: Biopharmaceutical Contract Manufacturing in Europe: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
  • Table 17.34: Biopharmaceutical Contract Manufacturing in Europe: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
  • Table 17.35: Biopharmaceutical Contract Manufacturing in Europe: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
  • Table 17.36: Biopharmaceutical Contract Manufacturing in Europe: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
  • Table 17.37: Biopharmaceutical Contract Manufacturing in Europe: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
  • Table 17.38: Biopharmaceutical Contract Manufacturing in China: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
  • Table 17.39: Biopharmaceutical Contract Manufacturing in China: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
  • Table 17.40: Biopharmaceutical Contract Manufacturing in China: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
  • Table 17.41: Biopharmaceutical Contract Manufacturing in China: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
  • Table 17.42: Biopharmaceutical Contract Manufacturing in China: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
  • Table 17.43: Biopharmaceutical Contract Manufacturing in China: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
  • Table 17.44: Intas Pharmaceuticals: Revenue from Operations, FY 2012 - FY 2016 (INR Million)
  • Table 17.45: Piramal Pharma Solutions: Annual Revenues, FY 2012- FY 2016 (INR Million)
  • Table 17.46: Shasun Pharma: Revenues by Geography, FY 2015-FY 2016 (INR Billion)
  • Table 17.47: Syngene: Annual Revenues FY 2012-Q1 2017 (INR Million)
  • Table 17.48: Biopharmaceutical Contract Manufacturing in India: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
  • Table 17.49: Biopharmaceutical Contract Manufacturing in India: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
  • Table 17.50: Biopharmaceutical Contract Manufacturing in India: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
  • Table 17.51: Biopharmaceutical Contract Manufacturing in India: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
  • Table 17.52: Biopharmaceutical Contract Manufacturing in India: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
  • Table 17.53: Biopharmaceutical Contract Manufacturing in India: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
  • Table 17.54: Asahi Glass Company: Annual Revenues, FY 2012-Q1 2017 (JPY Million)
  • Table 17.55: Biopharmaceutical Contract Manufacturing in Japan: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
  • Table 17.56: Biopharmaceutical Contract Manufacturing in Japan: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
  • Table 17.57: Biopharmaceutical Contract Manufacturing in Japan: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
  • Table 17.58: Biopharmaceutical Contract Manufacturing in Japan: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
  • Table 17.59: Biopharmaceutical Contract Manufacturing in Japan: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
  • Table 17.60: Biopharmaceutical Contract Manufacturing in Japan: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
  • Table 17.61: Samsung BioLogics: Revenues from CMO, FY 2013-Q1 2017 (KRW Billion)
  • Table 17.62: Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
  • Table 17.63: Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
  • Table 17.64: Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
  • Table 17.65: Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
  • Table 17.66: Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
  • Table 17.67: Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
  • Table 17.68: Bispecific Antibodies Pipeline: Distribution by Phase of Development
  • Table 17.69: Gene Therapy Pipeline: Distribution by Phase of Development
  • Table 17.70: Gene Therapy Contract Manufacturers: Distribution by Scale of Operation
  • Table 17.71: Gene Therapy Contract Manufacturers: Distribution by Location
  • Table 17.72: Global Biosimilars Pipeline: Distribution by Phase of Development
  • Table 17.73: Global Biosimilars Pipeline: Distribution by Phase of Development and Product Category
  • Table 17.74: Global Biosimilars Pipeline: Distribution by Phase of Development and Geography
  • Table 17.75: Biopharmaceutical CMOs: Cumulative Investment by Year
  • Table 17.76: Biopharmaceutical CMOs Investments: Distribution by Type
  • Table 17.77: Biopharmaceutical CMOs Partnerships: Distribution by Type of Partnerships
  • Table 17.78: Biopharmaceutical CMOs Partnerships: Cumulative Distribution by Year
  • Table 17.79: Capacity Analysis: Global Contract Biomanufacturing Capacity by Size of CMOs
  • Table 17.80: Capacity Analysis: Regional Distribution of Biopharmaceutical CMOs
  • Table 17.81: Capacity Analysis: Regional Production Capacity of Biopharmaceutical CMOs
  • Table 17.82: Capacity Analysis: Regional Contract Biomanufacturing Capacity
  • Table 17.83: Capacity Analysis: Percentage Distribution by Expression Systems Used
  • Table 17.84: Survey Analysis: Distribution of Respondents by Company Type
  • Table 17.85: Survey Analysis: Distribution of Respondents by Location of Headquarters
  • Table 17.86: Survey Analysis: Distribution of Respondents by Designation
  • Table 17.87: Survey Analysis: Distribution by Biologics Manufacturing Expertise
  • Table 17.88: Survey Analysis: Distribution by Scale of Manufacturing
  • Table 17.89: Survey Analysis: Distribution by Location of Production Facilities
  • Table 17.90: Survey Analysis: Distribution by Types of Expression Systems
  • Table 17.91: Survey Analysis: Distribution by Types of Bioreactors
  • Table 17.92: Survey Analysis: Distribution by Modes of Operation of Bioreactors
  • Table 17.93: Global Biopharmaceutical Contract Manufacturing Market, 2017-2027: Conservative Scenario (USD Billion)
  • Table 17.94: Global Biopharmaceutical Contract Manufacturing Market, 2017-2027: Base Scenario (USD Billion)
  • Table 17.95: Global Biopharmaceutical Contract Manufacturing Market, 2017-2027: Optimistic Scenario (USD Billion)
  • Table 17.96: Global Biopharmaceutical Contract Manufacturing Market for API, 2017-2027: Conservative Scenario (USD Billion)
  • Table 17.97: Global Biopharmaceutical Contract Manufacturing Market for API, 2017-2027: Base Scenario (USD Billion)
  • Table 17.98: Global Biopharmaceutical Contract Manufacturing Market for API, 2017-2027: Optimistic Scenario (USD Billion)
  • Table 17.99: Global Biopharmaceutical Contract Manufacturing Market for FDF, 2017-2027: Conservative Scenario (USD Billion)
  • Table 17.100: Global Biopharmaceutical Contract Manufacturing Market for FDF, 2017-2027: Base Scenario (USD Billion)
  • Table 17.101: Global Biopharmaceutical Contract Manufacturing Market for FDF, 2017-2027: Optimistic Scenario (USD Billion)
  • Table 17.102: Distribution of Global Biopharmaceutical Contract Manufacturing Market by Expression Systems, 2017-2027: Conservative Scenario (USD Billion)
  • Table 17.103: Distribution of Global Biopharmaceutical Contract Manufacturing Market by Expression Systems, 2017-2027: Base Scenario (USD Billion)
  • Table 17.104: Distribution of Global Biopharmaceutical Contract Manufacturing Market by Expression Systems, 2017-2027: Optimistic Scenario (USD Billion)
  • Table 17.105: Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017-2027: Conservative Scenario (USD Billion)
  • Table 17.106: Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017-2027: Base Scenario (USD Billion)
  • Table 17.107: Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017-2027: Optimistic Scenario (USD Billion)
  • Table 17.108: Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017, 2022 and 2027: Conservative Scenario (USD Billion)
  • Table 17.109: Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017, 2022 and 2027: Base Scenario (USD Billion)
  • Table 17.110: Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017, 2022 and 2027: Optimistic Scenario (USD Billion)

Listed Companies:

The following companies and organizations have been mentioned in the report:

  • 1. 3P Biopharmaceuticals
  • 2. Aalto Scientific
  • 3. AbbVie Contract Manufacturing
  • 4. AbGenomics
  • 5. Ablynx
  • 6. Abzena
  • 7. ACES Pharma
  • 8. Acticor Biotech
  • 9. Active Biotech
  • 10. Adar Biotech
  • 11. ADC Therapeutics
  • 12. Adimab
  • 13. Advanced BioScience Laboratories (ABL)
  • 14. Advanced Biotherapeutics Consulting (ABC)
  • 15. Affimed
  • 16. Affinity Life Sciences
  • 17. Agensys
  • 18. Ajinomoto Althea
  • 19. Albany Molecular Research (AMRI)
  • 20. Alberta Cell Therapy Manufacturing
  • 21. Alcami
  • 22. Aldevron
  • 23. Allele Biotechnology
  • 24. Alliance Medical Products
  • 25. Alligator Bioscience
  • 26. Allozyne
  • 27. ALMAC Group
  • 28. Altaris Capital Partners
  • 29. AmatsiQBiologicals
  • 30. AmbioPharm
  • 31. Ambrx
  • 32. AmBTU
  • 33. AMEGA Biotech
  • 34. Amgen
  • 35. Amneal Life Sciences
  • 36. AMSBIO
  • 37. Anogen
  • 38. apceth Biopharma
  • 39. Applied Biological Materials
  • 40. Applied Viromics
  • 41. Aptuit
  • 42. Arabio
  • 43. Asahi Glass
  • 44. Aspyrian Therapeutics
  • 45. Astellas Pharma
  • 46. AstraZeneca
  • 47. Asymchem
  • 48. Athenex Pharma Solutions
  • 49. Atlantic Bio GMP
  • 50. AURA Biotechnologies
  • 51. AUSTRIANOVA
  • 52. AutekBio
  • 53. Avecia
  • 54. Avid Biologics
  • 55. Avid Bioservices
  • 56. Bachem
  • 57. Baliopharm
  • 58. Batavia Biosciences
  • 59. Baxter BioPharma Solutions
  • 60. Bayer
  • 61. BCN Peptides
  • 62. Beckman Research Institute
  • 63. Beijing ABT Genetic Engineering Technology
  • 64. Bharat Serums And Vaccines
  • 65. BIBITEC
  • 66. Bicycle Therapeutics
  • 67. BINEX
  • 68. Bio Elpida
  • 69. Bioanalytical Sciences Department, Southern Research
  • 70. BioCell
  • 71. Biocon
  • 72. BioConnection
  • 73. Biofabri
  • 74. Biogen-Idec
  • 75. BioLineRx
  • 76. Biological and Cellular GMP Manufacturing Facility, City of Hope
  • 77. Biological E
  • 78. Biological Process Development Facility, University of Nebraska
  • 79. BioMARC
  • 80. Biomatik
  • 81. Biomay
  • 82. BIOMEVA
  • 83. BiondVax Pharmaceuticals
  • 84. BioPharmaceuticals Australia
  • 85. Biosynergy
  • 86. Bio-Synthesis
  • 87. BioTechLogic
  • 88. BioTechnique
  • 89. Biotechpharma
  • 90. Biotecnol
  • 91. Biotest
  • 92. BioVectra
  • 93. Biovian
  • 94. Blue Stream Laboratories
  • 95. Boehringer Ingelheim
  • 96. Boehringer Ingelheim BioXcellence
  • 97. Brammer Bio
  • 98. Bristol-Myers Squibb
  • 99. Bryllan
  • 100. BSP Pharmaceuticals
  • 101. Cambrex
  • 102. CARBOGEN AMCIS
  • 103. Catalent
  • 104. Catalent Biologics
  • 105. Catalent Pharma Solutions
  • 106. Cedarburg Pharmaceuticals
  • 107. Celgene
  • 108. Cell and Gene Therapy Catapult
  • 109. Cell Culture Company
  • 110. Cell Essentials
  • 111. Cell Therapies
  • 112. Cell Therapy and Regenerative Medicine, University of Utah
  • 113. Celldex Therapeutics
  • 114. CELLforCURE
  • 115. Cellin Technologies
  • 116. Cells for Sight, Stem Cell Therapy Research Unit, University College London
  • 117. Celltrion
  • 118. Cellular Dynamics International (a FUJIFILM company)
  • 119. Cellular Therapeutics
  • 120. Cellular Therapy Integrated Service, Case Western Reserve University
  • 121. Celonic
  • 122. Center for Biocatalysis and Bioprocessing, University of Iowa
  • 123. Center for Biomedical Engineering and Advanced Manufacturing, McMaster University
  • 124. Center for Cell and Gene Processing, Takara Bio
  • 125. Center for Cell and Gene Therapy, Baylor College of Medicine
  • 126. Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia (CHOP)
  • 127. Center of iPS Cell Research and Application, Kyoto University (CiRA)
  • 128. Centre for Commercialization of Regenerative Medicine
  • 129. Centrose
  • 130. Century Pharmaceuticals
  • 131. Cerbios-Pharma
  • 132. CEVEC Pharmaceuticals
  • 133. Charles River Laboratories
  • 134. ChemCon
  • 135. Chemi Peptides
  • 136. ChemPartner
  • 137. Children's GMP / GMP facility St. Jude Children's Research Hospital
  • 138. ChromaCon
  • 139. Cincinnati Children's Hospital Medical Center
  • 140. CinnaGen
  • 141. Clinical Biomanufacturing Facility, University of Oxford
  • 142. Clinical Research Facility, South London and Maudsley
  • 143. CMC Biologics
  • 144. Cobra Biologics
  • 145. Cognate BioServices
  • 146. Coldstream Laboratories
  • 147. Concord Biotech
  • 148. Concortis
  • 149. Cook Pharmica
  • 150. Corden Pharma
  • 151. Covance
  • 152. Creative Biogene
  • 153. Creative Biolabs
  • 154. Cryosite
  • 155. CytomX Therapeutics
  • 156. Cytovance Biologics
  • 157. Daiichi Sankyo
  • 158. Dalton Pharma Services
  • 159. Dishman Group
  • 160. DMBio
  • 161. Dow Pharmaceutical Solutions
  • 162. Dutalys
  • 163. EirGenix
  • 164. Eli Lilly
  • 165. Embio
  • 166. EMD Serono
  • 167. Emergent BioSolutions
  • 168. Emerson
  • 169. Encap Drug Delivery
  • 170. Endo Pharmaceuticals
  • 171. Epigen Biotech
  • 172. Esperance Pharmaceuticals
  • 173. EuBiologics
  • 174. EUCODIS Bioscience
  • 175. EUFETS
  • 176. Eurofins Central Global Laboratory
  • 177. Eurogentec
  • 178. Euticals
  • 179. Evonik
  • 180. Fabion Pharmaceuticals
  • 181. Ferro Pfanstiehl
  • 182. FinVector
  • 183. Formation Biologics
  • 184. Formosa Laboratories
  • 185. Foundation BioPharma
  • 186. Fraunhofer Institute for Cell Therapy and Immunology IZI
  • 187. French National Centre for Scientific Research, Université de Toulouse
  • 188. Frontage Laboratories
  • 189. F-star
  • 190. FUJIFILM Diosynth Biotechnologies
  • 191. Fusimab
  • 192. Fusion Antibodies
  • 193. Gadea Pharmaceutical Group
  • 194. Gala Biotech
  • 195. Gallus BioPharmaceuticals
  • 196. Ganymed Pharmaceuticals
  • 197. Gates Biomanufactuirng Facility
  • 198. GE Healthcare
  • 199. GEG Tech
  • 200. Gene and Cell Therapy Lab, Institute of Translational Health Sciences
  • 201. Gene Medicine Japan / Kobe Biomedical Accelerator
  • 202. Gene Transfer Vector Core (GTVC)
  • 203. Gene Transfer Vector Core, Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary
  • 204. Gene Transfer, Targeting and Therapeutics Core, Salk Institute for Biological Studies
  • 205. Gene Vector and Virus Core, Stanford Medicine
  • 206. GeneCure Biotechnologies
  • 207. GeneDetect
  • 208. Genentech
  • 209. Genethon
  • 210. GenIbet Biopharmaceuticals
  • 211. Genmab
  • 212. Génopoïétic
  • 213. GenVec
  • 214. Gilead Sciences
  • 215. GIPharma
  • 216. Glenmark Pharmaceuticals
  • 217. Glycotope Biotechnology
  • 218. GNH India
  • 219. Goodwin Biotechnology
  • 220. GOSH Cellular Therapy Laboratories, University College of London
  • 221. GP Pharm
  • 222. Grand River Aseptic Manufacturing
  • 223. Great Point Partners
  • 224. GreenPak Biotech
  • 225. Grünenthal
  • 226. GSEx, The Robinson Research Institute, University of Adelaide
  • 227. GSK
  • 228. GSK-Domantis
  • 229. GTP Technology
  • 230. Guy's and St Thomas' Facility
  • 231. HALIX
  • 232. Harvest Moon Pharmaceuticals
  • 233. Health Biotech
  • 234. Health Sciences Authority
  • 235. Heidelberg Pharma
  • 236. Hepalink
  • 237. Hetero Drugs
  • 238. Histocell
  • 239. Hisun Pharmaceuticals USA
  • 240. Ho Research Consortium
  • 241. Hong Kong Institute of Biotechnology
  • 242. Hope Center Viral Vectors Core, Washington University School of Medicine
  • 243. iBIOSOURCE
  • 244. Icagen
  • 245. IDDI
  • 246. IDT Biologika
  • 247. Igenica Biotherapeutics
  • 248. ImClone Systems
  • 249. ImmunoGen
  • 250. Immunomedics
  • 251. INC Research
  • 252. Indian Immunologicals
  • 253. Inhibrx
  • 254. Inno Biologics
  • 255. Innovent Biologics
  • 256. Intas Pharmaceuticals
  • 257. Integrity Bio
  • 258. International Joint Cancer Institute, Military Medical University
  • 259. Intertek
  • 260. Istituto Biochimico Italiano Giovanni Lorenzini
  • 261. JHL Biotech
  • 262. John Goldmann Centre for Cellular Therapy, Imperial College London
  • 263. Julphar Gulf Pharmaceutical Industries
  • 264. KABS Pharmaceutical Services
  • 265. Kairos Therapeutics
  • 266. Kamat Pharmatech
  • 267. KBI Biopharma
  • 268. Kemwell Biopharma
  • 269. Laboratory for Cell and Gene Medicine, Stanford University
  • 270. LAMPIRE Biological Laboratories
  • 271. Lentigen Technology (wholly owned subsidiary of Miltenyi Biotec)
  • 272. LFB BIOMANUFACTURING
  • 273. Lindis Biotech
  • 274. Lonza
  • 275. LuinaBio
  • 276. MabPlex
  • 277. MacroGenics
  • 278. Maine Biotechnology Services
  • 279. MassBiologics
  • 280. MaSTherCell
  • 281. MBI International
  • 282. MediaPharma
  • 283. MedImmune
  • 284. Medix Biochemica
  • 285. Menarini Biotech
  • 286. Merck
  • 287. Meridian Life Science
  • 288. Merrimack
  • 289. Merro Pharmaceutical
  • 290. Mersana Therapeutics
  • 291. Merus
  • 292. MGH Vector Core (Massachusetts General Hospital Neuroscience Center)
  • 293. MicroBiopharm Japan
  • 294. Microbix Biosystems
  • 295. Millennium Pharmaceuticals
  • 296. Minomic International
  • 297. Mitsubishi Gas Chemical Company
  • 298. Moderna Therapeutics
  • 299. Molecular and Cellular Therapeutics, University of Minnesota
  • 300. Molecular Partners
  • 301. MolMed
  • 302. MPI Research
  • 303. Multispan
  • 304. Mycenax Biotech
  • 305. Nantes Gene Therapy Institute
  • 306. Nascent Biologics
  • 307. National Cancer Institute (NCI)
  • 308. National Research Council of Canada
  • 309. NBE Therapeutics
  • 310. Neuland Laboratories
  • 311. NeuroCure (Viral Core Facility)
  • 312. NeuroFx
  • 313. Newcastle Cellular Therapies, University of Newcastle
  • 314. NextCell
  • 315. NHS Blood and Transplant
  • 316. NHSBT Birmingham
  • 317. Nikon Cell And Gene Therapy Contract Manufacturing
  • 318. Nitto Avecia Pharma Services
  • 319. Nordic Nanovector
  • 320. Norwegian Institute of Public Health
  • 321. Nova Laboratories
  • 322. Novartis
  • 323. Novasep
  • 324. Novex Innovations
  • 325. NovImmune
  • 326. Numab
  • 327. Oasmia Pharmaceutical
  • 328. OcellO
  • 329. OctoPlus
  • 330. Okairos (GSK subsidiary)
  • 331. Olon
  • 332. Omnia Biologics
  • 333. OncoMed
  • 334. OncoQuest
  • 335. OsoBio
  • 336. OXB Solutions (a business of Oxford BioMedica)
  • 337. Oxford BioMedica
  • 338. Oxford BioTherapeutics
  • 339. Oxford Genetics
  • 340. Pacific GMP
  • 341. Paktis Antibody Services
  • 342. Palatin Technologies
  • 343. Pamlico BioPharma
  • 344. Panacea Biotec
  • 345. Paragon Bioservices
  • 346. Parexel
  • 347. Particle Sciences
  • 348. PATH
  • 349. Patheon
  • 350. PCI Services (Biotec Services International)
  • 351. PCT, a Caladrius company
  • 352. Penn Vector Core, University of Pennsylvania
  • 353. Pfizer
  • 354. Pfizer CentreOne
  • 355. PharmAbcine
  • 356. PharmaBio
  • 357. PharmaCell
  • 358. Pharmedartis
  • 359. PharmiCell
  • 360. Philip S Orsino Facility for Cell Therapy, Princess Margaret Hospital
  • 361. Philochem
  • 362. PhotoBiotics
  • 363. Pierre Fabre
  • 364. Piramal Pharma Solutions
  • 365. PlasmidFactory
  • 366. Polymun Scientific
  • 367. Polypeptide Group
  • 368. Praxis Pharmaceutical
  • 369. Precision Antibody
  • 370. Precision Biologics
  • 371. PREMAS Biotech
  • 372. ProBioGen
  • 373. Productos Bio-Logicos
  • 374. Profectus BioSciences
  • 375. Progenics Pharmaceuticals
  • 376. ProJect Pharmaceutics
  • 377. ProMab Biotechnologies
  • 378. Protheragen
  • 379. Provantage End-to-End Services (Merck Millipore)
  • 380. PX'Therapeutics
  • 381. Pyramid Labs
  • 382. Quintiles
  • 383. Raymond G Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia
  • 384. Rayne's Cell Therapy Suite, King's College London
  • 385. Receptor Logic
  • 386. Redwood Bioscience
  • 387. Regeneron Pharmaceuticals
  • 388. Reliance Life Sciences
  • 389. Rentschler Biotechnologie
  • 390. Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation
  • 391. Richter-Helm BioLogics
  • 392. Rimedion
  • 393. Robertson Clinical and Translational Cell Therapy, Duke University
  • 394. Roche
  • 395. Roslin Cell Therapies
  • 396. Roswell Park Cancer Institute
  • 397. Royal DSM
  • 398. Royal Free, CCGTT
  • 399. SAB Technology
  • 400. SAFC
  • 401. Samsung BioLogics
  • 402. Sandoz
  • 403. Sanofi, CEPiA (Commercial & External Partnership, Industrial Affairs)
  • 404. Sanofi-Aventis
  • 405. Sanquin Pharmaceutical Services
  • 406. School of Medicine, University of Utah
  • 407. Scientific Protein Laboratories
  • 408. Sea Lane Biotechnologies
  • 409. Seattle Genetics
  • 410. Selexys Pharmaceuticals
  • 411. Senn Chemicals
  • 412. SGS Life Science Services
  • 413. Shire
  • 414. SignaGen Laboratories
  • 415. Singota Solutions
  • 416. Sirion Biotech
  • 417. SNBTS Cellular Therapy Facility
  • 418. Societa Italiana Corticosteroidi
  • 419. Sorrento Therapeutics
  • 420. Spirogen
  • 421. ST Pharm
  • 422. Stem CentRx
  • 423. Sutro Biopharma
  • 424. Sydney Cell and Gene Therapy
  • 425. Symbiosis Pharmaceutical Services
  • 426. Symbiosis, the Analytical Company
  • 427. SynCo Bio Partners
  • 428. Synergys Biotherapeutics
  • 429. Syngene
  • 430. SYNIMMUNE
  • 431. Synthon
  • 432. Sypharma
  • 433. System Biosciences
  • 434. Takara Bio
  • 435. Takeda
  • 436. The Chemistry Research Solution
  • 437. The Lentiviral Laboratory, USC School of Pharmacy
  • 438. The Native Antigen Company
  • 439. The Vector Core, University of North Carolina
  • 440. Therapure Biopharma (Therapure Biomanufacturing)
  • 441. THERAVECTYS
  • 442. Thermo Fisher Scientific
  • 443. Toyobo Biologics
  • 444. Translational Sciences
  • 445. TranXenoGen
  • 446. Trenzyme
  • 447. Trion Pharma
  • 448. Triphase Accelerator Corporation
  • 449. UC Davis GMP Laboratory
  • 450. UCB-Celltech
  • 451. UCLA Human Gene and Cell Therapy
  • 452. UMN Pharma
  • 453. University of Alabama Fermentation Facility
  • 454. University of Manchester
  • 455. University of Oxford Clinical BioManufacturing Facility
  • 456. University of Texas
  • 457. Upstate Stem Cell cGMP Facility, University of Rochester
  • 458. Valerion Therapeutics
  • 459. Valneva
  • 460. Vectalys
  • 461. Vector Biolabs
  • 462. Vector Core / GMP Facility, UC Davis
  • 463. Vector Core Lab / Human Applications Lab, Powell Gene Therapy Center, University of Florida
  • 464. Vector Core of Gene Therapy Laboratory of Nantes
  • 465. Vector Production Facility, Indiana University
  • 466. Vecura (Karolinska University Hospital )
  • 467. Vetter Pharma International
  • 468. VGXI
  • 469. Vibalogics
  • 470. Vigene Biosciences
  • 471. Viral Vector Core / Clinical Manufacturing Facility, Nationwide Children's Hospital
  • 472. Viral Vector Core, Duke University
  • 473. Viral Vector Core, Sanford Burnham Prebys Medical Discovery Institute
  • 474. Viral Vector Core, University of Iowa Carver College of Medicine
  • 475. Viral Vector Core, University of Massachusetts Medical School (UMMS)
  • 476. Virovek
  • 477. Vista Biologicals
  • 478. VIVEbioTECH
  • 479. Wacker Biotech
  • 480. Waisman Biomanufacturing
  • 481. WIL Research
  • 482. Wockhardt
  • 483. Wolfson Gene Therapy Unit, University College of London
  • 484. WuXi AppTec
  • 485. Wyeth
  • 486. X-BODY Biosciences
  • 487. Xellbiogene
  • 488. Xencor
  • 489. YposKesi
  • 490. Zhejiang HISUN Pharmaceuticals
  • 491. Zhengyang Gene Technology
  • 492. Zumutor Biologics
  • 493. Zydus Cadila
  • 494. Zymeworks
  • 495. ZymoGenetics
  • 496. Zyngenia
Back to Top